- \n
- Q1 2026 results in line with pre-announcement:<\/b>\n
- \n
- Net sales rise 2% to $492 million on a reported basis, and -1% at constant exchange rates (CER) vs. outlook for at least 1% CER growth<\/b><\/li>\n
- Sample technologies, QIAcuity and QDI deliver solid growth; QuantiFERON sales affected by significantly lower immigration testing demand<\/b><\/li>\n
- Diluted EPS of $0.33; adjusted diluted EPS of $0.54, also $0.54 CER in line with outlook<\/b><\/li>\n
- Adjusted operating income margin at 27.4%, as ongoing high level of profitability absorbs Parse investments and headwinds from tariffs and currency movements<\/b><\/li>\n<\/ul>\n<\/li>\n
- Updated full-year 2026 outlook reconfirmed: Net sales growth of about 1-2% CER and adj. diluted EPS of at least $2.43 CER<\/b><\/li>\n<\/ul>\n
VENLO, Netherlands–(BUSINESS WIRE<\/a>)–
\nQIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today reports full results for the first quarter of 2026 in line with the preliminary announcement, showing QIAGEN continuing to deliver strong profitability as adjusted diluted earnings per share (EPS) achieved the outlook. Sales trends were mixed, as lower QuantiFERON sales and cautious U.S. Life Sciences customer demand offset solid growth in other areas of the portfolio.<\/p>\n\nAs announced April 27, net sales for Q1 2026 rose 2% on a reported basis to $492 million, while sales at constant exchange rates (CER) were down 1%, compared with the outlook for at least 1% CER growth. Adjusted diluted EPS CER of $0.54 CER was in line with the outlook for at least $0.54 CER.<\/p>\n
\nQIAGEN\u2019s growth pillars together grew 4% CER compared to Q1 2025. Sample technologies delivered 9% CER growth compared with Q1 2025, and 3% CER growth excluding the Parse acquisition, supported by demand for automated consumables and instrument placements. QIAcuity digital PCR delivered double-digit CER sales growth on higher consumables and instrument sales over the year-ago period. QIAGEN Digital Insights (QDI) posted solid single-digit gains led by clinical bioinformatics. QIAstat-Dx sales declined 1% CER as expected against tough prior-year results. QIAstat-Dx consumables sales rose despite a weaker respiratory season on double-digit CER growth from recently launched Gastrointestinal and Meningitis panels in the U.S., while QIAstat-Dx instrument placements continued at a good level.<\/p>\n
\nQuantiFERON sales declined 5% CER from Q1 2025, mainly due to a significant decline in immigration testing demand in the United States and the Middle East. Trends remained solid in other patient testing groups. QIAGEN now expects QuantiFERON full-year 2026 sales to be unchanged at CER compared with 2025 sales of $503 million.<\/p>\n
\nQIAGEN updated on April 27 its full-year 2026 outlook for net sales to grow about 1-2% CER (previously at least 5% CER growth), driven by headwinds from the reduced QuantiFERON immigration testing demand, sustained caution among U.S. Life Sciences customers and increased geopolitical uncertainty. Adjusted diluted EPS are now expected to be at least $2.43 CER (previously at least $2.50 CER).<\/p>\n
\n\u201cQIAGEN made important progress across many areas of the portfolio in the first quarter, led by solid sales growth in Sample technologies, QIAcuity and QIAGEN Digital Insights,\u201d said Thierry Bernard, Chief Executive Officer of QIAGEN. \u201cQuantiFERON was affected by significant decline in immigration testing demand, but we view this as a rebasing of demand within this testing group during 2026 and not a change in the overall long-term opportunity for latent TB testing. We are focused on executing against our updated 2026 targets and positioning QIAGEN for faster growth in the second half of 2026.”<\/p>\n
\n\u201cOur profitability for the first quarter reflected disciplined execution in a challenging environment, as we managed the impact of supporting portfolio investments, as well as headwinds from tariffs, currency movements and measures to ensure reliable product supply,\u201d said Roland Sackers, Chief Financial Officer of QIAGEN. \u201cWe are focused on delivering solid profitable growth through efficiency gains combined with disciplined capital allocation and targeted investments that strengthen QIAGEN’s long-term growth potential and create value for shareholders.\u201d<\/p>\n
\nPlease find a PDF of the full press release incl. tables here<\/a>.<\/p>\n
QuantiFERON Spotlight Session on May 7, 2026<\/b><\/p>\n
\nQIAGEN plans to hold a virtual Spotlight Session to provide insights into our strategic priorities for QuantiFERON and an update on the latest product enhancements. The online event, which is a new format that builds on the recent Deep Dives series, is scheduled for Thursday, May 7, 2026, at 15:30 Frankfurt Time \/ 14:30 London Time \/ 9:30 New York Time<\/b>. Registration details and further information about the webcast are available in the Investor Relations section of the QIAGEN website (www.qiagen.com<\/a>), under Events and Presentations (https:\/\/corporate.qiagen.com\/English\/investor-relations\/events-and-presentations\/<\/a>), with a recording accessible after the event.<\/b><\/p>\n
Use of adjusted results<\/b><\/p>\n
\nQIAGEN reports adjusted results and constant exchange rate (CER) measures, along with other non-GAAP financial metrics, to provide deeper insight into business performance. These include adjusted gross margin and profit, adjusted operating income and expenses, adjusted operating income margin, adjusted net income, adjusted income before taxes, adjusted diluted EPS, adjusted tax rate and free cash flow. Free cash flow is calculated as cash flow from operating activities less capital expenditures for property, plant and equipment. Adjusted results are non-GAAP measures that QIAGEN views as complementary to GAAP-reported results. They exclude items considered outside of ongoing core operations, subject to significant period-to-period fluctuation, or that reduce comparability with competitors and historical performance. QIAGEN also uses these non-GAAP and constant currency measures internally for planning, forecasting, reporting and employee compensation purposes. These metrics enable consistent comparison of current and past performance, which QIAGEN has historically presented on an adjusted basis.<\/p>\n
About QIAGEN<\/b><\/p>\n
\nQIAGEN N.V., a Netherlands-based holding company, is a global leader in Sample to Insight solutions that enable customers to extract and analyze molecular information from biological samples containing the building blocks of life. Our Sample technologies isolate and process DNA, RNA and proteins from blood, tissue and other materials. Assay technologies prepare these biomolecules for analysis, while bioinformatics support the interpretation of complex data to deliver actionable insights. Automation solutions integrate these steps into streamlined, cost-effective workflows. QIAGEN serves more than 500,000 customers worldwide in the Life Sciences (academia, pharmaceutical R&D and industrial applications such as forensics) and molecular diagnostics (clinical healthcare). As of March 31, 2026, QIAGEN employed approximately 5,500 people across more than 35 locations. For more information, visit www.qiagen.com<\/a>.<\/p>\n
Forward-Looking Statement<\/b><\/p>\n
Certain statements contained in this press release may be considered forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended and Section 21E of the U.S. Securities Exchange Act of 1934, as amended. These statements can be identified by the use of forward-looking terminology such as \u201cbelieve\u201d, \u201chope\u201d, \u201cplan\u201d, \u201cintend\u201d, \u201cseek\u201d, \u201cmay\u201d, \u201cwill\u201d, \u201ccould\u201d, \u201cshould\u201d, \u201cwould\u201d, \u201cexpect\u201d, \u201canticipate\u201d, \u201cestimate\u201d, \u201ccontinue\u201d, \u201ctarget\u201d or other similar words. To the extent that any of the statements contained herein relating to QIAGEN\u2019s products, timing for launch and development, marketing and\/or regulatory approvals, financial and operational outlook, growth and expansion, acquisitions, collaborations, markets, strategy or operating results, including without limitation its expected net sales, net sales of particular products, net sales in particular geographies, adjusted net sales, expansion of adjusted operating income margin, returns to shareholders, progressive dividend payments, product portfolio management, product launches (including anticipated launches of our sequencing solutions, testing platforms, panels and systems), leveraging AI technology, improvements in operating and financial leverage, currency movements against the U.S. dollar, plans for investment in our portfolio and share repurchase commitments, our expectations relating to our adjusted tax rate, debt maturity and repayment, our ability to grow adjusted earnings per share at a greater rate than sales, our ability to improve operating efficiencies and maintain disciplined capital allocation, are forward-looking, such statements are based on current expectations and assumptions that involve a number of uncertainties and risks. Such uncertainties and risks include, but are not limited to, risks associated with our dependence on the development and success of new products; management of growth and expansion of operations (including the effects of currency fluctuations, tariffs, tax laws, regulatory processes and logistics and supply chain dependencies); variability of operating results; integration of acquired businesses; changes in relationships with customers, suppliers and strategic partners; competition; rapid or unexpected changes in technologies; fluctuations in demand for QIAGEN\u2019s products (including fluctuations due to general economic conditions, the level and timing of customers\u2019 funding, budgets and other factors, including delays or limits in the amount of reimbursement approvals or public health funding); our ability to obtain and maintain product regulatory approvals; difficulties in successfully adapting QIAGEN\u2019s products to integrated solutions and producing such products; the ability of QIAGEN to identify and develop new products and to differentiate and protect our products from competitors\u2019 products; market acceptance of new products and the integration of acquired technologies and businesses; actions of governments, global or regional economic developments, including inflation and changing interest rates, weather or transportation delays, natural disasters, cyber security breaches, political or public health crises and the resulting impact on the demand for our products and other aspects of our business, or other force majeure events; litigation risk, including patent litigation and product liability; debt service obligations; volatility in the public trading price of our common shares; as well as the possibility that expected benefits related to recent or pending acquisitions may not materialize as expected; and the other factors discussed under the heading \u201cRisk Factors\u201d in our most recent Annual Report on Form 20-F. For further information, please refer to the discussions in reports that QIAGEN has filed with, or furnished to, the U.S. Securities and Exchange Commission.<\/i><\/p>\n
\nSource: QIAGEN N.V.
\n
Category: Corporate<\/p>\n<\/p>\n
View source version on businesswire.com: <\/span>https:\/\/www.businesswire.com\/news\/home\/20260506886655\/en\/<\/a><\/span><\/p>\n
Investor Relations
\n<\/b>
e-mail: ir@QIAGEN.com<\/a><\/p>\nPublic Relations
\n<\/b>
e-mail: pr@QIAGEN.com<\/a><\/p>\nKEYWORDS:<\/b> New York Germany Europe United States North America<\/p>\n
INDUSTRY KEYWORDS:<\/b> Research Finance Clinical Trials Professional Services Biotechnology Other Health Health General Health Science<\/p>\n
- Sample technologies, QIAcuity and QDI deliver solid growth; QuantiFERON sales affected by significantly lower immigration testing demand<\/b><\/li>\n
- Net sales rise 2% to $492 million on a reported basis, and -1% at constant exchange rates (CER) vs. outlook for at least 1% CER growth<\/b><\/li>\n
![\"Logo\"](\"https:\/\/mms.businesswire.com\/media\/20260506886655\/en\/639304\/3\/QLogo_20mm_RGB.jpg\")
<\/td>\n<\/tr>\n